Fiera Capital (Canada)
ALXN

Fiera Capital (Canada)’s Alexion Pharmaceuticals ALXN Stock Holding History

Fiera Capital (Canada)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,356
Closed -$605K – 760
2018
Q3 		$605K Sell
4,356
-69
-2% -$8.66K ﹤0.01% 539
2018
Q2 		$549K Sell
4,425
-35
-0.8% -$4.09K ﹤0.01% 535
2018
Q1 		$497K Sell
4,460
-3,125
-41% -$374K ﹤0.01% 509
2017
Q4 		$907K Sell
7,585
-62,505
-89% -$7.61M ﹤0.01% 445
2017
Q3 		$9.83M Buy
+70,090
New +$9.52M 0.05% 238
2015
Q3 		– Sell
-1,500
Closed -$271K – 581
2015
Q2 		$271K Buy
+1,500
New +$259K ﹤0.01% 499
2014
Q4 		– Sell
-1,300
Closed -$216K – 462
2014
Q3 		$216K Sell
1,300
-500
-28% -$82.1K ﹤0.01% 441
2014
Q2 		$281K Sell
1,800
-6,100
-77% -$963K ﹤0.01% 469
2014
Q1 		$1.2M Sell
7,900
-4,000
-34% -$636K 0.01% 413
2013
Q4 		$1.58M Buy
11,900
+10,000
+526% +$1.2M 0.01% 382
2013
Q3 		$221K Buy
+1,900
New +$208K ﹤0.01% 343

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fiera Capital (Canada)'s ALXN Position: Q4 2018 in Review

Fiera Capital (Canada) sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 4,356 shares — an estimated $605K sold.

Fiera Capital (Canada) first reported a position in ALXN in Q3 2013 and held it in 11 quarters. The position peaked at $9.83M in Q3 2017. 609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Fiera Capital (Canada) reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Fiera Capital (Canada) sold 4,356 Alexion Pharmaceuticals shares in Q4 2018, an estimated $605K.
  • Fiera Capital (Canada) first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 11 quarters.
  • Fiera Capital (Canada)'s Alexion Pharmaceuticals position peaked at $9.83M in Q3 2017.
  • 609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Fiera Capital (Canada)'s 13F filing for Q4 2018, filed 12 Feb 2019.